| Type | Title | Date Released | |
|---|---|---|---|
8-K | Mangoceuticals Approves Series D Preferred Stock Offering and Sets Combined 2025 and 2026 Annual Meeting | ||
PRE 14A | Form PRE 14A | ||
8-K | Mangoceuticals Closes Registered Direct Offering Priced at 74% Premium | ||
424B5 | REGISTERED OFFERING | ||
4 | Cohen Jacob D. (Reporting) | ||
4 | JOHNSTON EUGENE M (Reporting) | ||
4 | Hamilton Alex P. (Reporting) | ||
SCHEDULE 13D/A | Cohen Jacob D. (Filed by) | ||
8-K | Mangoceuticals Secures $2.5 Million Strategic Investment in MangoRx IP Holdings; Receives Initial $1.75 Million Tranche | ||
8-K | Mangoceuticals, Inc. Terminates Business Combination Agreement with Nuclea Energy Inc. | ||
10-Q | Form 10-Q | ||
425 | Form 425 |